Allarity Therapeutics announced on October 9, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained a closing bid price of $1.00 or higher for 20 consecutive trading days from September 11 through October 9, 2024, successfully addressing the compliance issue that was first raised on June 18, 2024.The company is now focusing on advancing its stenoparib program, with ongoing Phase 2 trials in advanced ovarian cancer showing promising results. Stenoparib, an orally available dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, demonstrates unique therapeutic potential through its mechanism of inhibiting PARP and blocking Wnt pathway activation.CEO Thomas Jensen emphasized that resolving the compliance issue allows the company to concentrate on developing new treatment options for advanced ovarian cancer patients. Allarity holds exclusive global rights for stenoparib's development and commercialization, originally developed by Eisai Co. Ltd.

Allarity Therapeutics announced on October 9, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained a closing bid price of $1.00 or higher for 20 consecutive trading days from September 11 through October 9, 2024, successfully addressing the compliance issue that was first raised on June 18, 2024.The company is now focusing on advancing its stenoparib program, with ongoing Phase 2 trials in advanced ovarian cancer showing promising results. Stenoparib, an orally available dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, demonstrates unique therapeutic potential through its mechanism of inhibiting PARP and blocking Wnt pathway activation.CEO Thomas Jensen emphasized that resolving the compliance issue allows the company to concentrate on developing new treatment options for advanced ovarian cancer patients. Allarity holds exclusive global rights for stenoparib's development and commercialization, originally developed by Eisai Co. Ltd.